The Comparative Clinical Study of Gamisoyosan on Anxiety of Generalized Anxiety Disorder According to Dosage Form

This study has been completed.
Sponsor:
Information provided by:
Korea Health Industry Development Institute
ClinicalTrials.gov Identifier:
NCT01285115
First received: January 26, 2011
Last updated: NA
Last verified: October 2010
History: No changes posted

January 26, 2011
January 26, 2011
December 2008
June 2010   (final data collection date for primary outcome measure)
Hamilton Anxiety Scale(HAM-A) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
The HAM-A (Hamilton Anxiety Scale) is a widely used interview scale that measures the severity of a patient's anxiety, based on 14 parameters, including anxious mood, tension, fears, insomnia, somatic complaints and behavior at the interview.
Same as current
No Changes Posted
  • State-Trait Anxiety Inventory(STAI) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    The State-Trait Anxiety Inventory (STAI) was initially conceptualized as a research instrument for the study of anxiety in adults. It is a self-report assessment device which includes separate measures of state and trait anxiety.
  • Beck Depression Inventory(BDI) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    BDI is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression. Each question has a set of at least four possible answer choices, ranging in intensity. When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity.
  • Symptom Checklist-90-Revised(SCL-90R) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    The Symptom Checklist-90-R (SCL-90-R) is a relatively brief self-report psychometric instrument (questionnaire). It is designed to evaluate a broad range of psychological problems and symptoms of psychopathology. It is also used in measuring the progress and outcome of psychiatric and psychological treatments or for research purposes.
  • WHO Quality of Life Abbreviated(WHOQOL-BREF) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Quality of life is used to evaluate the general well-being of individuals and societies.
  • Heart Rate Variability(HRV) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Heart rate variability (HRV) is a physiological phenomenon where the time interval between heart beats varies. It is measured by the variation in the beat-to-beat interval.
  • PSWQ [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    The Penn State Worry Questionaire is a 16-item inventory assess worry and anxiety
  • GSES [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    The General Self-Efficacy Scale is a 10-item psychometric scale that is designed to assess optimistic self-beliefs to cope with a variety of difficult demands in life.
  • RSE [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Rosenberg Self-Esteem Scale is questionnaire that popular lore recognizes just "high" self-esteem and "low" self-esteem, the Rosenberg Self-Esteem Scale quantify it in more detail, and feature among the most widely used systems for measuring self-esteem.
Same as current
Not Provided
Not Provided
 
The Comparative Clinical Study of Gamisoyosan on Anxiety of Generalized Anxiety Disorder According to Dosage Form
Phase 3 The Comparative Clinical Study of Gamisoyosan on Anxiety of Generalized Anxiety Disorder According to Dosage Form : A Randomized, Double Blind, Parallel-controlled Trial

In this randomized, double blinded, Parallel-controlled study, the investigators planned to give Gamisoyosan extract, Gamisoyosan extract powder or controlled medication on Anxiety of generalized anxiety disorder according to dosage form.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Generalized Anxiety Disorder
  • Drug: Placebo
    AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
  • Drug: KyungBangn-Gamisoyosan-x-gwarip
    AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
    Other Name: standard code for item : 200005799
  • Drug: KyungBangn Gamisoyosan
    AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
    Other Name: standard code for item: 200005591
  • Placebo Comparator: Placebo; corn flour,
    • raw material total contents(500㎎) cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)
    • shape, type: extract(brown)
    • usage, content: adults;three times a day each sack taken before or between meals
    • dose, standard: for each sack 7.67g
    • storage : airtight container, stored in room temperature
    • expiration date : after manufacture 36 month
    • macufacturing company: KyungBangnShinYak inc.
    Intervention: Drug: Placebo
  • Active Comparator: Gamisoyosan extract
    • name of product: KyungBangn-Gamisoyosan-x-gwarip
    • standard code for item : 200005799
    • shape, type: extract(grayish brown)
    • usage, content : adults;three times a day , each sack taken before or between meals
    • dose, standard: 7.67g for each sack
    • storage : airtight container, stored in room temperature expiration date : after manufacture 36 month macufacturing company: KyungBangnShinYak inc.
    Intervention: Drug: KyungBangn-Gamisoyosan-x-gwarip
  • Active Comparator: Gamisoyosan extract powder
    • name of product: KyungBangn Gamisoyosan
    • standard code for item: 200005591
    • shape, type: powder(brown)
    • usage, content: adults;three times a day each sack taken before or between meals
    • dose, standard: 7.67g for each sack
    • storage : airtight container, stored in room temperature
    • expiration date : after manufacture 36 month
    • macufacturing company: KyungBangnShinYak inc.
    Intervention: Drug: KyungBangn Gamisoyosan
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
147
July 2010
June 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female aged 20-65
  • (Structured Clinical Interview for DSM-Ⅳ Axis Ⅰ Disorder, SCID-Ⅰ) subjects who meet Structured Clinical Interview for DSM-Ⅳ Axis Ⅰ Disorder, SCID-Ⅰof generalized anxiety disorder

Exclusion Criteria:

  • Currrent or past history of delusions, halucination
  • Past history of at least one manic episode, hypomanic episode, or mixed episode
  • Current or past history of alcohol abuse or alcohol dependence history
  • Taking substances(e.g. antianxiety drugs, antidepressant, antipsychotic drug, steroids, female hormonal drug, L-dopa, digitalis, bromide, cyclosporin, disulfiram, isoniazid, yohimbine) which might affect symptoms
  • Medical conditions(e.g. myocardial infarction,brain tumor, multiple sclerosis, pancreatic disease, hyperthyroidism, hypothyroidism, Addison disease, Cushing disease, rheumarthritis, cancer, CVA, epilepsy, anemia, pituitarium disease, Vit B12 deficiency disease, PMS) that might affect symptoms
  • Current with hepatoma, hepatic cirrhosis, chronic renal failure, congestive heart failure
  • Pregnancy, lactation, women not using medically accepted means of birth control
  • Considered not apt to carry out clinical trial
Both
20 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT01285115
B082005
Yes
the president of Korea Health Industry Development Institute, Korea Health Industry Development Institute
Korea Health Industry Development Institute
Not Provided
Principal Investigator: In-Chul Jung, Ph.D Oriental Hospital of Daejon University
Korea Health Industry Development Institute
October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP